ProVerum
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $108.0Mattributed |
|---|---|
| Latest round | series-b, $74.1M, 2025-08-01attributed |
| Founded | 2017 |
| Headquarters | Dublin, Ireland |
| Industry | healthtech |
| Stage | series-b+ |
| Website | proverum.com |
ProVerum's ProVee System is a nitinol prostatic urethral stent that gently reshapes an enlarged prostate to relieve urinary symptoms of BPH. It serves urologists and men with moderate-to-severe BPH wanting treatment without cutting or burning. Its edge is an FDA-approved stent placed via an endoscope-sized system. Domain currently parked.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-08-01 | series-b | $74.1M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $74.1M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $108.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | proverum.com, read 2026-05-07 |
| Description | self-reported | proverum.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.